CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
choline fenofibratedrug
Likely dose
choline fenofibrate 135 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00673881
NCT00673881Phase 2Completed
CompareCT.gov

ABT-335 (Choline Fenofibrate)Reverse Cholesterol Transport (RCT) Study

Radiant Research·interventional·Posted May 7, 2008·Updated Apr 20, 2011

In Brief

A Phase 2 clinical trial evaluating choline fenofibrate for Dyslipidemia. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The objectives of the study are: 1. To evaluate the effect of ABT-335 (choline fenofibrate) on several parameters of RCT (reverse cholesterol transport) in men and post-menopausal women diagnosed with dyslipidemia (i.e., low high-density lipoprotein \[HDL\] cholesterol levels and elevated triglyceride \[TG\] concentrations). 2. To evaluate longitudinal changes in several parameters of RCT in subjects with low HDL. 3. To obtain pilot data for power calculations for subsequent comparative study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 7, 2008
Enrollment StartMar 1, 2008
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.2 years ago

Interventions

choline fenofibratedrug

135 mg choline fenofibrate daily(oral, capsule)